| 1.725 0 (0%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 18.68 | 1-year : | 21.82 |
| Resists | First : | 16 | Second : | 18.68 |
| Pivot price | 10.44 |
|||
| Supports | First : | 7.17 | Second : | 1.72 |
| MAs | MA(5) : | 10.6 | MA(20) : | 11.01 |
| MA(100) : | 7.29  |
MA(250) : | 7.78 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 78.3 |
D(3) : | 77.9 |
| RSI | RSI(14): 46.8 |
|||
| 52-week | High : | 28.19 | Low : | 1.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ EIGR ] has closed above bottom band by 45.5%. Bollinger Bands are 99.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.02 - 10.07 | 10.07 - 10.11 |
| Low: | 9.85 - 9.92 | 9.92 - 9.97 |
| Close: | 9.9 - 10.01 | 10.01 - 10.09 |
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Mon, 01 Apr 2024
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection - GlobeNewswire
Thu, 04 Jan 2024
Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split - PR Newswire
Thu, 09 Nov 2023
Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update - PR Newswire
Tue, 12 Sep 2023
Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta - PR Newswire
Mon, 14 Aug 2023
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update - PR Newswire
Thu, 29 Jun 2023
Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 11.8 (%) |
| Held by Institutions | 43.8 (%) |
| Shares Short | 34 (K) |
| Shares Short P.Month | 42 (K) |
| EPS | -58.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.09 |
| Profit Margin | 0 % |
| Operating Margin | -527.6 % |
| Return on Assets (ttm) | -52.5 % |
| Return on Equity (ttm) | -226 % |
| Qtrly Rev. Growth | -20.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 9.91 |
| EBITDA (p.s.) | -56.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -83 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -0.18 |
| PEG Ratio | 0 |
| Price to Book value | -9.26 |
| Price to Sales | 1 |
| Price to Cash Flow | -0.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|